Randomized, double-blind, placebo-controlled study (no washout period required) where
subjects receive either 3 months of tetracycline or 3 months of placebo. After the 3 month
primary endpoint, in the follow-up period, patients will be assigned to the alternate
treatment for 3 months with blind maintained.